Brainstorm Cell Therapeutics Inc. (BCLI)
Chart Events
Performance Outlook
| Previous Close | 3.2100 |
| Open | 3.1700 |
| Bid | 3.1400 x 1000 |
| Ask | 3.1700 x 900 |
| Day's Range | 3.0300 - 3.2300 |
| 52 Week Range | 3.0300 - 17.9500 |
| Volume | 635,471 |
| Avg. Volume | 1,183,243 |
| Market Cap | 111.808M |
| Beta (5Y Monthly) | 0.08 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.0660 |
| Earnings Date | May 05, 2021 - May 10, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 11.50 |
Fair Value
Related Research
- Simply Wall St.
Do Institutions Own Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Shares?
A look at the shareholders of Brainstorm Cell Therapeutics Inc. ( NASDAQ:BCLI ) can tell us which group is most...
- Zacks Small Cap Research
BCLI: Positive Proof-of-Concept Data for NurOwn in Progressive Multiple Sclerosis…
By David Bautz, PhD NASDAQ:BCLI READ THE FULL BCLI RESEARCH REPORT Business Update Positive Proof-of-Concept Data for NurOwn in Progressive MS On March 24, 2021, BrainStorm Cell Therapeutics, Inc. (NASDAQ:BCLI) announced positive proof-of-concept data for NurOwn in patients with progressive multiple sclerosis (MS). The trial achieved the primary endpoint of safety and encouraging results were seen in multiple secondary, functional endpoints. The Phase 2 trial was a multicenter, open label trial that enrolled 20 patients, with 18 treated and 16 completing the study. Two of the enrolled patients decided against continuing in the trial before dosing began, with one patient withdrawing following dosing due to non-specific symptoms and another due to back/leg pain. Following a 10-week run-in period, patients were dosed with 1-1.25 x 106 MSC-NTF cells three times at 2-month intervals. Patients were followed for 28 weeks following the first treatment. The secondary functional endpoints
- Benzinga
Why Is It Moving? Looking Into Why Brainstorm Cell's Stock is Trading Higher Today
The Price And Volume Action In Brainstorm Cell's Stock Today Brainstorm Cell's (NASDAQ:BCLI) stock has been rising Wednesday, up 5.58% to a price of $4.42. The stock's volume is currently 4.47 million, which is roughly 465.03% of its recent 30-day volume average of 962.18 thousand. Why It's Moving Benzinga Pro's real-time breaking news service shows some insight into what is affecting shares: Brainstorm Cell Therapeutics shares are trading higher after the company announced topline data from the company's Phase 2 trial evaluating NurOwn as a treatment for progressive MS. Perspective On Recent Price Action The 50-day moving average price of Brainstorm Cell's stock was $5.23 when this article was published. The stock reached a high of $17.95 and a low of $3.1 in the past 52 weeks. Benzinga Pro provides investors with timely and accurate explanations of why a stock is moving. Subscribe to receive real-time alerts explaining stock price movements. Click here to learn more. See more from BenzingaClick here for options trades from Benzinga12 Health Care Stocks Moving In Wednesday's Pre-Market Session© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
